Here, we developed an experimental strategy to characterize the molecular networks that are operating within the tumor to mediate anti-CTLA4 induced tumor regression, and identify drugs that target these mechanisms and are able to increase therapeutic response rates. Here, CTLA4 is linked to neoplasm.